4 results
The aim of the study is to evaluate the efficacy of sensor augmented pump (SAP) therapy with MiniMed* 640G and SmartGuard* in preventing hypoglycemic events in comparison with continuous subcutaneous insulin infusion (CSII) therapy in type 1…
Comparison of steady-state cysteamine-trough WBC cystine levels between Cystagon® and RP103 over 3 months for each treatment period.
- To assess the pharmacokinetic profile of cysteamine base after single dose administration of the new sustained-release cysteamine bitartrate (PO-001) to healthy volunteers, in comparison with Cystagon® and Procysbi®.- To collect safety/…
This Phase Ia/Ib study will evaluate the safety, pharmacokinetics, immunogenicity (as applicable for study biotherapeutics), preliminary activity, and biomarkers of GDC-6036 as a single agent (Arm A) and in combination with other anti-cancer…